IPCA Laboratories

IPCA Laboratories Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of IPCA Laboratories (IPCALAB.NS) as of Nov 1, 2026 is 0.22. In the previous year, Net Debt to Free Cash Flow Ratio was -0.03 — a change of -882.44% (higher).

Net Debt/FCF

0.22

YoY

-882.44%

Last updated:

Net Debt to Free Cash Flow Ratio of IPCA Laboratories is 2026 0.22 . Net Debt to Free Cash Flow Ratio of IPCA Laboratories was 2025 -0.03 . It decreases by -882.44% higher compared to the previous year.

The IPCA Laboratories Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2019
-0.07 INR
Jan 1, 2020
0.03 INR
Jan 1, 2021
-0.79 INR
Jan 1, 2022
-1.58 INR
Jan 1, 2023
-2.75 INR
Jan 1, 2024
0.55 INR
Jan 1, 2025
-0.03 INR
Jan 1, 2026
0.22 INR
The IPCA Laboratories Net Debt/FCF history
YEARNet Debt/FCFYoY
0.22-882.44%
-0.03-105.24%
0.55-119.92%
-2.75+74.23%
-1.58+100.18%
-0.79-2,491.97%
0.03-150.29%
-0.07-105.27%
1.24-53.06%
2.65+144.65%
1.08-115.71%
-6.90-209.77%
6.28—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IPCA Laboratories Stock analysis

What does IPCA Laboratories do? Ipca Laboratories Ltd. generates revenue through the manufacturing and marketing of over 350 pharmaceutical formulations and approximately 80 active pharmaceutical ingredients (APIs), including Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts, and Propranolol. The company sells its branded products such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, and Venpower in more than 100 countries globally. Its subsidiaries, Ipca Pharmaceuticals, Inc., Ipca Laboratories (U.K.) Ltd, and Tonira Exports Limited, support the distribution and sales of these products across international markets. The company's primary customers are healthcare providers, hospitals, and pharmacies in over 100 countries, purchasing both generic APIs and branded formulations. Manufacturing units in India produce APIs and formulations, with the firm's subsidiaries facilitating global market access. The therapeutic segments covered by its products include cardiovascular, antimalarial, and gastrointestinal treatments, among others, driven by the demand for cost-effective pharmaceutical solutions. IPCA Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IPCA Laboratories stock

Net Debt to Free Cash Flow Ratio of IPCA Laboratories is 0.22 in 2026.

Net Debt to Free Cash Flow Ratio of IPCA Laboratories changed from -0.03 to 0.22, representing a -882.44% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio IPCA Laboratories since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's IPCA Laboratories with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — IPCA Laboratories

All Key Metrics — IPCA Laboratories